Ecnoglutide (XW003) Phase 1 Trial in Adolescents Completed

A clinical trial update for ecnoglutide, also known as XW003, was recorded on May 20, 2026. The trial, titled "A Study of XW003 Injection in Chinese Adolescents With Obesity," is registered as NCT07143227 on ClinicalTrials.gov. The study is listed as Phase 1 and its status is marked as completed as of this update. The trial enrolled Chinese adolescents with obesity as its study population. Ecnoglutide remains an unapproved compound currently in research stages, and no approved medical use has been established. This update reflects only the trial's status change to completed and does not include any reported results, outcomes, or efficacy data. No safety findings, adverse events, or trial results have been disclosed as part of this update. Readers should note that a completed status refers only to the trial reaching its concluding phase, not to the availability or interpretation of data. Further details on outcomes, if released, would typically appear in subsequent publications or registry updates. For additional context on ecnoglutide, including its research background and current regulatory standing, readers can consult the compound overview.